Porcine endogenous retrovirus released bya bioartificial liver infects primary human cells

Liver International

Volumn 29, Issue 10, 2009, Pages 1553-1561

  Frühauf, Jan Henning ^a   Mertsching, Heike ^b   Giri, Shibashish ^a   Frühauf, Nils Roman ^c   Bader, Augustinus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c German Foundation of Organ Transplantation (DSO)   (Germany)

Author keywords

Bioartificial liver; Flat membrane bioreactor; Porcine endogenous retrovirus; Xenotransplantatione

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOARTIFICIAL LIVER; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL; LIVER RESECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; VIRUS TRANSMISSION;

ANIMALS; CELLS, CULTURED; ENDOGENOUS RETROVIRUSES; ENDOTHELIAL CELLS; HEPATOCYTES; HUMANS; LIVER, ARTIFICIAL; SWINE;

EID: 73349093740     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02087.x     Document Type: Article

References (61)

1. Patience C, Takeuchi Y, Weiss R.A. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282-6.
2. Kanai H, Marushima H, Kimura N, et al. Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy. Artif Organs 2006; 31: 148-51.
3. De Bartolo L, Bader A. Review of a flat membrane bioreactor as a bioartificial liver. Ann Transpl 2001; 6: 40-6.
4. Gerlach J, Schnoy N, Smith MD, et al. Hepatocyte culture between woven capillary networks: a microscopy study. Artif Organs 1994; 18: 226-30.
5. Flendrig LM, Sommeijer D, Ladiges NC, et al. Commercially available media for flushing extracorporeal bioartificial liver systems prior to connection to the patient's circulation: an in vitro comparative study in two and three dimensional porcine hepatocyte cultures. Int J Artif Organs 1998; 21: 467-72.
6. McKane BW, Ramachandran S, Yang J, et al. Xenoreactive anti-Gal alpha(1,3)Gal antibodies prevent porcine endogenous retrovirus infection of human in vivo. Hum Immunol 2003; 64: 708-17.
7. Rozga J, Podesta L, LePage E, et al. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 1993; 342: 898-9.
8. Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16: 60-5.
9. Uchino J, Matsue H, Takahashi M, et al. A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. ASAIO Trans 1991; 37: M337-8.
10. Kuddus R, Patzer JF II, Lopez R, et al. Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 2002; 73: 420-9.
11. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-4.
12. Maki T, Monaco A.P. Porcine islets xenotransplantation utilizing a vascularized bioartificial pancreas. Ann Transpl 1997; 2: 69-71.
13. Dinsmore JH, Manhart C, Raineri R, et al. No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells. Transplantation 2000; 15: 1382-9.
14. Louz D, Bergmans HE, Loos BP, Hoeben R.C. Reappraisal of biosafety risks posed by PERVs in xenotransplantation. Rev Med Virol 2008; 18: 53-65.
15. Weiss R.A. Xenografts and retroviruses. Science 1999; 285: 1221-2.
16. Akiyoshi DE, Denaro M, Zhu H, et al. Identification of a full-length cDNA for an endogenous retrovirus of miniature swine. J Virol 1998; 72: 4503-7.
17. Van der Laan LJ, Lockey C, Griffeth BC, et al. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature 2000; 7: 90-4.
18. Martin U, Kiessig V, Blusch JH, et al. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 1998; 29: 692-4.
19. Wilson CA, Wong S, Muller J, et al. Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J Virol 1998; 72: 3082-7.
20. Paradis K, Langford G, Long Z, et al. Search for crossspecies transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 1999; 285: 236-41.
21. Heneine W, Tibell A, Switzer WM, et al. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998; 352: 695-9.
22. Patience C, Patton GS, Takeuchi Y, et al. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 1998; 352: 699-701.
23. Fiebig U, Stephan O, Kurth R, Denner J. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? Virology 2003; 307: 406-13.
24. Takeuchi Y, Patience C, Magre S, et al. Host range and interference studies of three classes of pig endogenous retrovirus. J Virol 1998; 72: 9986-91.
25. Ericsson TA, Takeuchi Y, Templin C, et al. Identification of receptors for pig endogenous retrovirus. Proc Natl Acad Sci USA 2003; 100: 6759-64.
26. Marcucci KT, Martina Y, Harrison F, Wilson CA, Salomon D.R. Functional hierarchy of two L domains in porcine endogenous retrovirus (PERV) that influence release and infectivity. Virology 2008; 375: 637-45.
27. Le Tissier P, Stoye JP, Takeuchi Y, Patience C,Weiss R.A. Two sets of human-tropic pig retrovirus. Nature 1997; 389: 681-2.
28. Blusch JH, Patience C, Martin U. Pig endogenous retroviruses and xenotransplantation. Xenotransplantation 2002; 9: 242-51.
29. Pitkin Z, Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999; 23: 829-33.
30. Falasca E, Adami V, Astori G, et al. Porcine endogenous retrovirus does not infect human cells using a bioartificial liver model system. Transpl Proc 2001; 33: 1780-1.
31. Kuddus R, Patzer JF, Lopez R, et al. Valuation of transmission of porcine endogenous retrovirus into patients subjected to hemoperfusion using an extracorporeal bioartificial liver support system. Transpl Proc 2001; 33: 1976.
32. Di Nicuolo G, Van de Kerkhove M-P, Hoekstra R, et al. No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMCbioartificial liver. Xenotransplantation 2005; 12: 286-92.
33. Dunn JC, Yarmush ML, Koebe HG, Tompkins R.G. Hepatocyte function and extracellular matrix geometry: longterm culture in a sandwich configuration. FASEB J 1989; 3: 174-7.
34. Bader A, Zech K, Crome O, et al. Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals. Xenobiotica 1994; 24: 623-33.
35. Bader A, Hansen T, Kirchner G, et al. Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 2000; 129: 331-42.
36. Bader A, Steinhoff G, Strobl K, et al. Engineering of human vascular aortic tissue based on a xenogeneic starter matrix. Transplantation 2000; 70: 7-14.
37. Silver J, Maudru T, Fujita K, Repaske R. An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. Nucleic Acids Res 1993; 21: 3593-4.
38. Liu Q, Liu Z, Dalakas E. Prevalence of porcine endogenous retrovirus in Chinese pig breeds and in patients treated with a porcine liver cell-based bioreactor. World J Gastroenterol 2005; 11: 4727-30.
39. Van de Kerkhove MP, Di Florio E, Scuderi V, et al. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transpl 2003; 12: 563-8.
40. Wang HH, Wang YJ, Liu HL, Liu J. Detection of PERV by polymerase chain reaction and its safety in bioartificial liver support system. World J Gastroenterol 2006; 12: 1287-91.
41. Irgang M, Sauer IM, Karlas A, et al. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clin Virol 2003; 28: 141-54.
42. Kardassis D, Zeillinger K, Pascher A, et al. Clinical extracorporeal hybrid liver support - phase I study with primary porcine liver cells. Xenotransplantation 2003; 10: 460-9.
43. Nishitai R, Ikai I, Shiotani T, et al. Absence of PERV 0infection in baboons after transgenic porcine liver perfusion. J Surg Res 2005; 124: 45-51.
44. Levy MF, Argaw T, Wilson CA, et al. No evidence of PERV infection in healthcare workers exposed to transgenic porcine liver extracorporeal support. Xenotransplantation 2007; 14: 309-15.
45. Hermida-Prieto M, Domenech N, Moscoso I, et al. Lack of cross-species transmission of porcine endogenous retrovirus (PERV) to transplant recipients and abattoir workers in contact with pigs. Transplantation 2007; 84: 548-50.
46. Tacke SJ, Kurth R, Denner J. Porcine endogenous retroviruses inhibit human immune cell function: risk for xenotransplantation? Virology 2000; 268: 87-93.
47. Tacke S, Specke V, Stephen O, et al. Porcine endogenous retroviruses: diagnostic assays and evidence for immunosuppressive properties. Transpl Proc 2000; 32: 1166.
48. Jungman A, Tonjes R.R. Retrotransposition: another obstacle for xenotransplantation. Transpl Proc 2008; 40: 596-7.
49. Leib-Mosch C, Brack-Werner R, Werner T, et al. Endogenous retroviral elements in human D.N.A. Cancer Res 1990; 50: 5636-42.
50. Denner J. Is porcine endogenous retrovirus (PERV) transmission still relevant. Transpl Proc 2008; 40: 587-9.
51. Ericsson TA, Takeuchi Y, Templin C, et al. Identification of receptors for pig endogenous retrovirus. PNAS 2003; 100: 6759-64.
52. Mackey L. Feline leukaemia virus and its clinical effects in cats. Vet Rec 1975; 96: 5-11.
53. Teich N, Wyke J, Mak T, Bernstein A, Hardy W. Pathogenesis of retrovirus-induced disease. In Weiss RA, Teich N, Varmus HE, Coffin JM, eds. RNA Tumor Viruses, 2nd edn. New York, NY: Cold Spring Harbor Laboratory Press, 1984; 901-3.
54. Denner J. Immunosuppression by retroviruses: implications for xenotransplantation. Ann N Y Acad Sci 1998; 862: 76-86.
55. Weiss R.A. Cross-species infections. Curr Top Microbiol Immunol 2003; 278: 47-71.
56. Bader A, Knop E, Boker KH, et al. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. Naunyn Schmiedebergs. Arch Pharmacol 1996; 353: 461-73.
57. Nyberg SL, Hibbs JR, Hardin JA, Germer JJ, Persing D.H. Transfer of porcine endogenous retrovirus across hollow fiber membranes: significance to a bioartificial liver. Transplantation 1999; 67: 1251-5.
58. Xu H, Sharma A, Okabe J, et al. Serologic analysis of antiporcine endogenous retroviruses immune responses in humans after ex vivo transgenic pig liver perfusion. ASAIO J 2003; 49: 407-16.
59. Claudia R, Ballauff A, Lange R, Erhard J. Heterotopic auxiliary liver transplantation in a 3 year old boy with acute liver failure and aplastic anemia. Transplantation 1997; 64: 658-60.
60. Strain AJ, Neuberger J.M. A bioartificial liver state of art. Science 2002; 295: 1005-9.
61. Mertsching H, Karim N, Haverich A, Bader A. Investigations on biological safety and immunologic aspects of chimeric bioartificial vessels in xenotransplantation. Transpl Proc 2000; 32: 1165.